PANCREAS
PANCREAS
复制标题
DOI：
10.1111/ajt.13667
复制
发表时间：
2016-01-01
影响因子：
8.8
通讯作者：
Kasiske, B. L.
中科院分区：
文献类型：
--
作者：
Kandaswamy, R.;Skeans, M. A.;Kasiske, B. L.
尽管胰腺移植数量在过去十年中稳步下降，但与前一年相比，2014年新增移植数量有所增加，尤其是单独胰腺移植（PTA）和胰肾联合移植。在过去的两年里，新教师的数量也有所增加。这一趋势能否持续，还有待观察。2014年的重大事件包括实施新的胰腺分配系统和制定胰腺移植衰竭的统一定义。同时，总体胰腺移植率和结果继续改善。肾移植后胰腺的大量下降仍然是一个严重的问题。SRTR在过去两年中没有在特定项目的报告中发表胰腺移植失败的数据。虽然这在不久的将来不会改变，但接受统一的移植失败定义是恢复移植失败报告的关键的第一步。手术和免疫方面的持续改进和创新，将是保持胰腺移植作为治疗胰岛素依赖型糖尿病的可行选择的关键。随着胰岛移植和人工胰腺等糖尿病替代疗法的发展，将并发症最小化的改善结果比以往任何时候都更加重要。
Even though pancreas transplant numbers have steadily declined over the past decade, new listings increased in 2014 compared with the previous year, notably for pancreas transplant alone (PTA) and simultaneous pancreas-kidney transplant. The number of new PTAs also increased over the past two years. Whether this is a sustainable trend remains to be seen. Significant events in 2014 included implementation of a new pancreas allocation system and development of a proposed uniform definition of pancreas graft failure. Meanwhile, overall pancreas transplant rates and outcomes continued to improve. Substantial decline in pancreas after kidney transplants remains a serious concern. SRTR has not published pancreas graft failure data in the program-specific reports for the past two years. While this will not change in the near future, the acceptance of a uniform definition of graft failure is a crucial first step toward resuming graft failure reporting. Continued improvements and innovation, both surgical and immunological, will be critical to keep pancreas transplant as a viable option for treatment of insulin-dependent diabetes. As alternative therapies for diabetes such as islet transplant and artificial pancreas are evolving, improved outcomes with minimizations of complications are more important than ever.